KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

AbbVie (ABBV) Other Operating Expenses (2016 - 2025)

Historic Other Operating Expenses for AbbVie (ABBV) over the last 14 years, with Q2 2025 value amounting to $24.0 million.

  • AbbVie's Other Operating Expenses changed N/A to $24.0 million in Q2 2025 from the same period last year, while for Sep 2025 it was $4.3 billion, marking a year-over-year change of. This contributed to the annual value of $7.0 million for FY2024, which is 9608.94% down from last year.
  • As of Q2 2025, AbbVie's Other Operating Expenses stood at $24.0 million.
  • AbbVie's Other Operating Expenses' 5-year high stood at $4.4 billion during Q1 2021, with a 5-year trough of -$500.0 million in Q3 2021.
  • Moreover, its 5-year median value for Other Operating Expenses was $24.0 million (2025), whereas its average is $760.9 million.
  • As far as peak fluctuations go, AbbVie's Other Operating Expenses surged by 15294.12% in 2022, and later crashed by 174.42% in 2023.
  • Over the past 5 years, AbbVie's Other Operating Expenses (Quarter) stood at -$500.0 million in 2021, then surged by 100.2% to $1.0 million in 2022, then skyrocketed by 16800.0% to $169.0 million in 2023, then tumbled by 95.86% to $7.0 million in 2024, then skyrocketed by 242.86% to $24.0 million in 2025.
  • Its last three reported values are $24.0 million in Q2 2025, $4.2 billion for Q1 2025, and $7.0 million during Q4 2024.